Breaking Boundaries: Amber Therapeutics Secures $100 Million in Series A Funding for Groundbreaking Neuromodulation Therapies

We are thrilled to announce that Amber Therapeutics has successfully raised $100 million in funding to advance our mission of developing transformative neuromodulation therapies. Founded in 2021, Amber Therapeutics is uniquely positioned in the UK as the only company designing and manufacturing long-term implantable medical devices. With the recent acquisitions of Finetech Medical Limited and Bioinduction Ltd, we have expanded our capabilities and expertise, further establishing our commitment to addressing significant unmet clinical needs. This substantial funding will accelerate the development of Amber UI, our groundbreaking therapy focused on restoring normal physiological function in women suffering from mixed urinary incontinence. By leveraging our multidisciplinary team, which blends extensive medical device experience with a culture dedicated to innovation, we aim to set a new standard of care in the realm of women's health. The investment will support robust clinical trials, enhance our product development processes, and accelerate our go-to-market strategies as we work to deliver solutions that enhance the quality of life for patients. We are excited about the journey ahead and are grateful for the support of our investors, whose belief in our vision propels us forward in our quest for transformative outcomes in healthcare.